Skip to content
DataLookout
Menu

NCT03260491

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 53 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 90 words Show 6 more changesShow less
    • Primary completion date changed from estimate of Mar 31, 2026 to Dec 1, 2025
    • Study completion pushed from Dec 31, 2026 to Jul 30, 2027
    • Secondary endpoints: details revised at 1 of 23 entries
    • Site details revised at 3 of 37 sites
    • Collaborators: details revised at 1 of 1 entry
    • Study description expanded, about 3 words
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 309 to confirmed 312
    • Site details revised at 37 of 37 sites
    v52
  3. Minor Site details revised at 1 of 37 sitesv51
  4. Minor Study sites: 36 to 37v50
  5. Minor Site details revised at 8 of 36 sitesv49
Show 29 earlier versionsHide 29 earlier versions
  1. Notable Eligibility criteria expanded, about 26 wordsv48 Show 4 more changesShow less
    • Primary endpoints revised (5)
    • Study sites: 22 to 36
    • Secondary endpoints revised (23)
    • Study title revised
  2. Study Status, Sponsor/Collaboratorsv47
  3. Minor Secondary endpoints revised (23)v46
  4. Notable Trial status: Active, Not Recruiting to Recruitingv45 Show 11 more changesShow less
    • Primary completion date: Jan 28, 2022 to Mar 31, 2026
    • Eligibility criteria expanded, about 866 words
    • Primary endpoints revised (5)
    • Enrollment target: 271 to 309
    • Study sites: 20 to 22
    • Study completion date: Dec 31, 2024 to Dec 31, 2026
    • Interventions: U3-1402 (CTM-1 Lyo-DP) (Drug), U3-1402 (CTM-3 Lyo-DP) (Drug), U3-1402 (FL-DP) (Drug) to HER3-DXd (CTM-1 Lyo-DP) (Drug), HER3-DXd (CTM-3 Lyo-DP) (Drug), HER3-DXd (FL-DP) (Drug)
    • Secondary endpoints: 28 to 23
    • Study description expanded, about 29 words
    • Study title revised
    • Study arms: 9 to 10
  5. Minor Study completion date: Dec 31, 2023 to Dec 31, 2024v44
  6. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 264 to confirmed 271
    • Study sites: 22 to 20
    v43
  7. Notable Trial status: Active, Not Recruiting to Recruiting
    • Primary endpoints revised (5)
    • Study sites: 20 to 22
    • Secondary endpoints: 27 to 28
    v42
  8. Minor Enrollment target: 216 to 264v41
  9. Notable Eligibility criteria expanded, about 150 wordsv40 Show 5 more changesShow less
    • Primary endpoints: 3 to 5
    • Study completion date: Nov 1, 2023 to Dec 31, 2023
    • Interventions: U3-1402 (Drug) to U3-1402 (CTM-1 Lyo-DP) (Drug), U3-1402 (CTM-3 Lyo-DP) (Drug), U3-1402 (FL-DP) (Drug)
    • Secondary endpoints revised (27)
    • Study arms: 8 to 9
  10. Minor Primary completion date changed from estimate of Dec 31, 2021 to Jan 28, 2022
    • Study completion date: Dec 31, 2023 to Nov 1, 2023
    v39
  11. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 22 to 20
    v29
  12. Minor Site details revised at 1 of 22 sitesv28
  13. Minor Site details revised at 1 of 22 sitesv27
  14. Minor Site details revised at 2 of 22 sitesv26
  15. Minor Study sites: 20 to 22v25
  16. Minor Study sites: 18 to 20v24
  17. Minor Study sites: 14 to 18v23
  18. Notable Eligibility criteria expanded, about 32 wordsv22 Show 5 more changesShow less
    • Primary endpoints revised (3)
    • Enrollment target: 198 to 216
    • Primary completion date: Oct 31, 2021 to Dec 31, 2021
    • Study completion date: Oct 31, 2023 to Dec 31, 2023
    • Secondary endpoints: 31 to 27
  19. Minor Study sites: 12 to 14v21
  20. Notable Primary endpoints revised (3)
    • Eligibility criteria expanded, about 3 words
    v17
  21. Notable Enrollment target: 130 to 198
    • Eligibility criteria shortened, about 10 words
    • Study sites: 11 to 12
    • Study arms: 1 to 8
    v15
  22. Minor Study sites: 10 to 11v14
  23. Minor Study sites: 7 to 10v13
  24. Minor Study sites: 5 to 7v12
  25. Notable Eligibility criteria expanded, about 9 words
    • Study sites: 4 to 5
    v10
  26. Notable Enrollment target: 63 to 130
    • Primary completion date: Feb 28, 2020 to Oct 31, 2021
    • Study completion date: Feb 28, 2020 to Oct 31, 2023
    v9
  27. Minor Site details revised at 1 of 4 sitesv7
  28. Minor Study sites revised (4)v5
  29. Study Status, Contacts/Locationsv4
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose-limiting toxicities (DLTs) during dose escalation
Timeframe: 21 days of Cycle 1
Summary of adverse events during dose escalation
Timeframe: By the global end of trial date, approximately within 36 months
Overall response rate (ORR) assessed by Blinded Independent Central Review (BICR) Committee during dose expansion (Dose Expansion Cohorts 1, 2, 3a, 3b, and Cohort 5)
Timeframe: Approximately within 36 months
Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)
Timeframe: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)
Timeframe: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.

Secondary (23)

Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalation
Time of maximum concentration (Tmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalation
Area under the serum concentration-time curve from time 0 to 21 days (AUC[0-21]) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalation
Overall response rate (ORR) during dose escalation
Disease control rate (DCR) during dose escalation
Show 18 moreShow less
Duration of response (DOR) during dose escalation
Time to response (TTR) during dose escalation
Progression free survival (PFS) during dose escalation
Overall Survival (OS) during dose escalation
Summary of adverse events during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)
Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Dose Expansion Cohorts 1-3 and Cohort 5)
Time of maximum concentration (Tmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)
Area under the serum concentration-time curve from time 0 to 21 days (AUC[0-21]) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Dose Expansion Cohorts 1-3 and Cohort 5)
Overall response rate (ORR) by Investigator during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)
Disease control rate (DCR) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)
Duration of response (DOR) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)
Time to response (TTR) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)
Progression free survival (PFS) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)
Overall survival (OS) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)
Percentage of participants who are anti-drug antibody (ADA)-positive (baseline and post-baseline) and Percentage of participants who have treatment-emergent ADA during dose expansion (Cohort 4)
Mean Change from Baseline in the NSCLC-SAQ Total Score (Cohort 5)
Proportions of Deteriorated, Stable, or Improved Symptoms from NSCLC-SAQ (Cohort 5)
Proportions of Deteriorated, Stable, or Improved Symptoms from PRO-CTCAE (Cohort 5)

Arms and interventions

Dose Escalation: Cohort 1, 3.2 mg/kgExperimental

Participants in the Dose Escalation Cohort 1 will receive HER3-DXd intravenously (IV) once every three weeks at 3.2 mg/kg.

Dose Escalation: Cohort 2, 4.8 mg/kgExperimental

Participants in Dose Escalation Cohort 2 will receive HER3-DXd intravenously (IV) once every three weeks at 4.8 mg/kg.

Dose Escalation: Cohort 3, 5.6 mg/kgExperimental

Participants in Dose Escalation Cohort 3 will receive HER3-DXd intravenously (IV) once every three weeks at 5.6 mg/kg.

Dose Escalation: Cohort 4, 6.4 mg/kgExperimental

Participants in Dose Escalation Cohort 3 will receive HER3-DXd intravenously (IV) once every three weeks at 6.4 mg/kg.

Dose Expansion: Cohort 1, EGFR mutantExperimental

Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE).

Dose Expansion: Cohort 2, EGFR wild-typeExperimental

Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE).

Dose Expansion: Cohort 3a, EGFR mutantExperimental

Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE) or, if applicable, adjusted RDE (aRDE).

Dose Expansion: Cohort 3b, EGFR mutantExperimental

Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive HER3-DXd IV once every three weeks following an up-titration regimen (Cycle 1, Day 1: 57% of RDE or aRDE; Cycle 2, Day 1: 86% of RDE or, if applicable aRDE; Cycle 3 and subsequent cycles, Day 1: 114% of RDE or aRDE).

Dose Expansion: Cohort 4, EGFR mutantExperimental

Participants with NSCLC (including any histology other than small-cell or combined small-cell and non-small cell) with an EGFR-activating mutation will receive HER3-DXd IV at 5.6 mg/kg every 3 weeks.

Dose Expansion: Cohort 5, KRAS-G12C mutant NSCLCExperimental

Participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation and that have progressed on the most recent line of therapy will receive HER3-DXd IV at 5.6 mg/kg every 3 weeks.

Drugs: HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)

Sites

37 sites in 6 countries

United States 16, Spain 9, Japan 5, South Korea 3, Taiwan 3, Netherlands 1